Skip to main content

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
Cancel
×
×
Home
  • Home
Chapter
  • Print publication year: 2006
  • Online publication date: July 2010

15 - Assays and molecular determinants of cellular drug resistance

from Part III - Evaluation and treatment
    • By Monique L. den Boer, Associate Professor, Molecular Pediatric Oncology Head, Research Laboratory Pediatric Oncology, Erasmus MC–Sophia Children's Hospital, University Medical Center Rotterdam, Department of Pediatric Oncology and Hematology, Rotterdam, the Netherlands, Rob Pieters, Professor and Head, Department of Pediatric Oncology and Hematology, Erasmus MC–Sophia Children's Hospital, University Medical Center Rotterdam, Rotterdam, the Netherlands
  • Edited by Ching-Hon Pui
  • Publisher: Cambridge University Press
  • https://doi.org/10.1017/CBO9780511471001.016
  • pp 414-438
Export citation
Summary

Introduction

Chemotherapy for children with acute leukemia has improved impressively over the past 40 years, despite the use of similar agents throughout this period. The efficacy of antileukemic drugs depends largely on their dosages and schedules of administration. It also depends on the intrinsic and acquired resistance of leukemic cells to drug treatment. Knowledge of the factors contributing to cellular drug resistance was slow to accumulate, but has grown rapidly over the last two decades. This chapter describes some of the prominent methods for assessing drug resistance in leukemia patients and reviews progress in elucidating the molecular determinants of this phenomenon.

Drug cytotoxicity assays

In the early 1980s, drug cytotoxicity was mainly evaluated by clonogenic assays such as colony-forming unit assays and stromal cell layer-supported long-term marrow cultures. These time-consuming assays rely on the in vitro proliferating capacity of cells, a characteristic that in practice is restricted to acute and chronic myeloid blasts. The most frequent type of leukemia in children, acute lymphoblastic leukemia (ALL), cannot be tested with assays of this type because the cells lack any in vitro proliferating capacity. Moreover, the resistance of resting, nondividing cells, which may be an important source of treatment failure, is not detectable with these proliferation-based assays.

Dye exclusion or differential staining cytotoxicity assay

In 1983, Weisenthal and co-workers introduced the dye exclusion assay (DEA), which enables one to test the cytotoxicity of drugs in nonclonogenic cells. This assay exploits trypan-blue dye, which selectively diffuses into damaged cells with permeabilized cell membranes.

Recommend this book

Email your librarian or administrator to recommend adding this book to your organisation's collection.

Childhood Leukemias
  • Online ISBN: 9780511471001
  • Book DOI: https://doi.org/10.1017/CBO9780511471001
Please enter your name
Please enter a valid email address
Who would you like to send this to *

CAPTCHA *

Skip to the audio challenge
×
References
Weisenthal, L. M. & Lippman, M. E.Clonogenic and nonclonogenic in vitro chemosensitivity assays. Cancer Treat Rep, 1985; 69: 615–32.
Weisenthal, L. M., Marsden, J. A., Dill, P. L., et al.A novel dye exclusion method for testing in vitro chemosensitivity of human tumors. Cancer Res, 1983; 43: 749–57.
Bird, M. C., Bosanquet, A. G., & Gilby, E. D.Semi-micro adaptation of a 4-day differential staining cytotoxicity (DiSC) assay for determining the in-vitro chemosensitivity of haematological malignancies. Leuk Res, 1986; 10: 445–9.
Pieters, R., Huismans, D. R., Leyva, A., et al.Comparison of the rapid automated MTT-assay with a dye exclusion assay for chemosensitivity testing in childhood leukaemia. Br J Cancer, 1989; 59: 217–20.
Mosmann, T.Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods, 1983; 65: 55–63.
Kaspers, G. J. L., Veerman, A. J. P., Pieters, R., et al.Mononuclear cells contaminating leukaemic samples tested for cellular drug resistance using the methyl-thiazol-tetrazolium assay. Br J Cancer, 1994; 70: 1047–52.
Tosi, P., Visani, G., Ottaviani, E., et al.Biological and clinical significance of in vitro prednisolone resistance in adult acute lymphoblastic leukemia. Eur J Cancer, 1996; 57: 134–41.
Kirkpatrick, D. L., Duke, M., & Goh, T. S.Chemosensitivity testing of fresh human leukemia cells using both a dye exclusion assay and a tetrazolium dye (MTT) assay. Leuk Res, 1990; 14: 459–66.
Rots, M. G., Pieters, R., Kaspers, G. J., et al.Differential methotrexate resistance in childhood T-versus common/preB-acute lymphoblastic leukemia can be measured by an in situ thymidylate synthase inhibition assay, but not by the MTT assay. Blood, 1999; 93: 1067–74.
Larsson, R., Kristensen, J., Sandberg, C.et al.Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia using a fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer, 1992; 50: 177–85.
Nygren, P., Kristensen, J., Jonsson, B.et al.Feasibility of the fluorometric microculture cytotoxicity assay (FMCA) for cytotoxic drug sensitivity testing of tumor cells from patients with acute lymphoblastic leukemia. Leukemia, 1992; 6: 1121–8.
Campana, D., Manabe, A., & Evans, W. E.Stroma-supported immunocytometric assay (SIA): a novel method for testing the sensitivity of acute lymphoblastic leukemia cells to cytotoxic drugs. Leukemia, 1993; 7: 482–8.
Kaspers, G. J. L., Veerman, A. J. P., Pieters, R., et al.In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood, 1997; 90: 2723–9.
Mollgard, L., Tidefelt, U., Sundman-Engberg, B.et al.In vitro chemosensitivity testing in acute non lymphocytic leukemia using the bioluminescence ATP assay. Leuk Res, 2000; 24: 445–52.
Cline, M. J., & Rosenbaum, E.Prediction of in vivo cytotoxicity of chemotherapeutic agents by their in vitro effect on leucocytes from patients with acute leukemia. Cancer Res, 1968; 28: 2516–21.
Bosanquet, A. G.Correlations between therapeutic response of leukaemias and in-vitro drug-sensitivity assay. Lancet, 1991; 337: 711–14.
Hongo, T., Yajima, S., Sakurai, M., et al.In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia. Blood, 1997; 89: 2959–65.
Pieters, R., Huismans, D. R., Loonen, A. H., et al.Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia. Lancet, 1991; 338: 399–403.
Frost, B. M., Nygren, P., Gustafsson, G.et al.Increased in vitro cellular drug resistance is related to poor outcome in high-risk childhood acute lymphoblastic leukaemia. Br J Haematol, 2003; 122: 376–85.
Kaspers, G. J. L., Pieters, R., Zantwijk, C. H., et al.Prednisolone resistance in childhood acute lymphoblastic leukemia: vitro-vivo correlations and cross-resistance to other drugs. Blood, 1998; 92: 259–66.
Schmiegelow, K., Nyvold, C., Seyfarth, J.et al.Post-induction residual leukemia in childhood acute lymphoblastic leukemia quantified by PCR correlates with in vitro prednisolone resistance. Leukemia, 2001; 15: 1066–71.
De Haas, V., Kaspers, G. J., Oosten, L.et al.Is there a relationship between in vitro drug resistance and level of minimal residual disease as detected by polymerase chain reaction at the end of induction therapy in childhood acute lymphoblastic leukaemia ?Br J Haematol, 2002; 118: 1190–1.
Klumper, E., Pieters, R., Veerman, A. J. P., et al.In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia. Blood, 1995; 86: 3861–8.
Rots, M. G., Pieters, R., Peters, G. J., et al.Methotrexate resistance in relapsed childhood acute lymphoblastic leukaemia. Br J Haematol, 2000; 109: 629–34.
Hongo, T., Yamada, S., Yajima, S.et al.Biological characteristics and prognostic value of in vitro three-drug resistance to prednisolone, L-asparaginase, and vincristine in childhood acute lymphoblastic leukemia. Int J Hematol, 1999; 70: 268–77.
Boer, M. L., Harms, D. O., Pieters, R.et al.Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. J Clin Oncol, 2003; 21: 3262–8.
Zwaan, C. M., Kaspers, G. J. L., Pieters, R.et al.Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia. Blood, 2000; 96: 2879–86.
Yamada, S., Hongo, T., Okada, S.et al.Clinical relevance of in vitro chemoresistance in childhood acute myeloid leukemia. Leukemia, 2001; 15: 1892–7.
Zwaan, C. M., Kaspers, G. J., Pieters, R.et al.Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities. Blood, 2002; 100: 3352–60.
Klumper, E., Pieters, R., Kaspers, G. J. L., et al.In vitro chemosensitivity assessed with the MTT assay in childhood acute non-lymphoblastic leukemia. Leukemia, 1995; 9: 1864–9.
Klumper, E., Ossenkoppele, G. J., Pieters, R.et al.In vitro resistance to cytosine arabinoside, not to daunorubicin, is associated with the risk of relapse in de novo acute myeloid leukaemia. Br J Haematol, 1996; 93: 903–10.
Norgaard, J. M., Olesen, G., Kristensen, J. S., et al.Leukaemia cell drug resistance and prognostic factors in AML. Eur J Haematol, 1999; 63: 219–24.
Pui, C. H. & Evans, W. E.Acute lymphoblastic leukemia. N Engl J Med, 1998; 339: 605–15.
Pieters, R., Boer, M. L., Durian, M.et al.Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia – implications for treatment of infants. Leukemia, 1998; 12: 1344–8.
Dördelmann, M., Reiter, A., Borkhardt, A.et al.Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood, 1999; 94: 1209–17.
Ramakers-van Woerden, N. L., Pieters, R., Rots, M. G., et al.Infants with acute lymphoblastic leukemia: no evidence for high methotrexate resistance. Leukemia, 2002; 16: 949–51.
Maung, Z. T., Reid, M. M., Matheson, E.et al.Corticosteroid resistance is increased in lymphoblasts from adults compared with children: preliminary results of in vitro drug sensitivity study in adults with acute lymphoblastic leukaemia. Br J Haematol, 1995; 91: 93–100.
Styczynski, J., Pieters, R., Huismans, D. R., et al.In vitro drug resistance profiles of adult versus childhood acute lymphoblastic leukemia. Br J Haematol, 2000; 110: 813–18.
Göker, E., Lin, J. T., Trippett, T.et al.Decreased polyglutamylation of methotrexate in acute lymphoblastic leukemia blasts in adults compared to children with this disease. Leukemia, 1993; 7: 1000–4.
Ramakers-van Woerden, N. L., Pieters, R., Hoelzer, D.et al.In vitro drug resistance profile of Philadelphia positive acute lymphoblastic leukemia is heterogeneous and related to age: a report of the Dutch and German Leukemia Study Groups. Med Ped Oncol, 2002; 38: 379–86.
Masson, E., Relling, M. V., Synold, T. W., et al.Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. J Clin Invest, 1996; 97: 73–80.
Niehues, T., Kapaun, P., Harms, D. O., et al.A classification based on T cell selection-related phenotypes identifies a subgroup of childhood T-ALL with favorable outcome in the COALL studies. Leukemia, 1999; 13: 614–17.
Ferrando, A. A., Neuberg, D. S., Staunton, J.et al.Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell, 2002; 1: 75–87.
Pui, C. H., Ribeiro, R. C., Campana, D.et al.Prognostic factors in the acute lymphoid and myeloid leukemias of infants. Leukemia, 1996; 10: 952–6.
Stam, R. W., Boer, M. L., Meijerink, J. P., et al.Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. Blood, 2003; 101: 1270–6.
Yamauchi, H., Iwata, N., Omine, M.et al.In vitro methotrexate polyglutamate formation is elevated in acute lymphoid leukemia cells compared with acute myeloid leukemia and normal bone marrow cells. Nippon Ketsueki Gakkai Zasshi, 1988; 51: 766–73.
Lin, J. T., Tong, W. P., Trippett, T. M., et al.Basis for natural resistance to methotrexate in human acute non-lymphocytic leukemia. Leuk Res, 1991; 15: 1191–6.
Goker, E., Kheradpour, A., Waltham, M.et al.Acute monocytic leukemia: a myeloid leukemia subset that may be sensitive to methotrexate. Leukemia, 1995; 9: 274–6.
Argiris, A., Longo, G. S., Gorlick, R.et al.Increased methotrexate polyglutamylation in acute megakaryocytic leukemia (M7) compared to other subtypes of acute myelocytic leukemia. Leukemia, 1997; 11: 886–9.
Rots, M. G., Pieters, R., Jansen, G.et al.A possible role for methotrexate in the treatment of childhood acute myeloid leukaemia, in particular for acute monocytic leukaemia. Eur J Cancer, 2001; 37: 492–8.
Ramakers-van Woerden, N. L., Pieters, R., Slater, R. M., et al.In vitro drug resistance and prognostic impact of p16INK4A/P15INK4B deletions in childhood T-cell acute lymphoblastic leukaemia. Br J Haematol, 2001; 112: 680–90.
Ramakers-van Woerden, N. L., Pieters, R., Loonen, A. H., et al.TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. Blood, 2000; 96: 1094–9.
Stams, W. A., Boer, M. L., Beverloo, H. B., et al.Sensitivity to L-asparaginase is not associated with expression levels of asparagine synthetase in t(12;21)+ pediatric ALL. Blood, 2003; 101: 2743–7.
Whitehead, V. M., Payment, C., Cooley, L.et al.The association of the TEL-AML1 chromosomal translocation with the accumulation of methotrexate polyglutamates in lymphoblasts and with ploidy in childhood B-progenitor cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Leukemia, 2001; 15: 1081–8.
Kaspers, G. J. L., Smets, L. A., Pieters, R.et al.Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: results of an in vitro study. Blood, 1995; 85: 751–6.
Ito, C., Kumagai, M., Manabe, A.et al.Hyperdiploid acute lymphoblastic leukemia with 51 to 65 chromosomes: a distinct biological entity with a marked propensity to undergo apoptosis. Blood, 1999; 93: 1183–9.
Synold, T. W., Relling, M. V., Boyett, J. M., et al.Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. J Clin Invest, 1994; 94: 1996–2001.
Whitehead, V. M., Vuchich, M. J., Lauer, S. J., et al.Accumulation of high levels of methotrexate polyglutamates in lymphoblasts from children with hyperdiploid (greater than 50 chromosomes) B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood, 1992; 80: 1316–23.
Hongo, T., Okada, S., Inoue, N.et al.Two groups of Philadelphia chromosome-positive childhood acute lymphoblastic leukemia classified by pretreatment multidrug sensitivity or resistance in in vitro testing. Int J Hematol, 2002; 76: 251–9.
Biondi, A., Cimino, G., Pieters, R.et al.Biological and therapeutic aspects of infant leukemia. Blood, 2000; 96: 24–33.
Zwaan, C. M., Kaspers, G. J., Pieters, R.et al.Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome. Blood, 2002; 99: 245–51.
Yamada, S., Hongo, T., Okada, S.et al.Distinctive multidrug sensitivity and outcome of acute erythroblastic and megakaryoblastic leukemia in children with Down syndrome. Int J Hematol, 2001; 74: 428–36.
Tissing, W. J., Meijerink, J. P., Boer, M. L., et al.Molecular determinants of glucocorticoid sensitivity and resistance in acute lymphoblastic leukemia. Leukemia, 2003; 17: 17–25.
Kaspers, G. J. L., Pieters, R., & Veerman, A. J. P.Glucocorticoid resistance in childhood leukemia. Int J Pediat Hematol/Oncol, 1997; 4: 583–96.
Haarman, E. G., Kaspers, G. J., Pieters, R.et al.In vitro glucocorticoid resistance in childhood leukemia correlates with receptor affinity determined at 37 degrees C, but not with affinity determined at room temperature. Leukemia, 2002; 16: 1882–4.
Tonko, M., Ausserlechner, M. J., Bernhard, D.et al.Gene expression profiles of proliferating versus G1/G0 arrested human leukemia cells suggest a mechanism for glucocorticoid-induced apoptosis. FASEB J, 2001; 15: 693–9.
Ramdas, J., Liu, W., & Harmon, J. M.Glucocorticoid-induced cell death requires autoinduction of glucocorticoid receptor expression in human leukemic T cells. Cancer Res, 1999; 59: 1378–85.
Breslin, M. B., Geng, C. D., & Vedeckis, W. V.Multiple promoters exist in the human GR gene, one of which is activated by glucocorticoids. Mol Endocrinol, 2001; 15: 1381–95.
Yudt, M. R., Jewell, C. M., Bienstock, R. J., et al.Molecular origins for the dominant negative function of human glucocorticoid receptor beta. Mol Cell Biol, 2003; 23: 4319–30.
de Lange, P., Segeren, C. M., Koper, J. W., et al.Expression in hematological malignancies of a glucocorticoid receptor splice variant that augments glucocorticoid receptor-mediated effects in transfected cells. Cancer Res, 2001; 61: 3937–41.
Rivers, C., Levy, A., Hancock, J., et al.Insertion of an amino acid in the DNA-binding domain of the glucocorticoid receptor as a result of alternative splicing. J Clin Endocrinol Metab, 1999; 84: 4283–6.
Ray, D. W., Davis, J. R., White, A., et al.Glucocorticoid receptor structure and function in glucocorticoid-resistant small cell lung carcinoma cells. Cancer Res, 1996; 56: 3276–80.
Moalli, P. A., Pillay, S., Krett, N. L., et al.Alternatively spliced glucocorticoid receptor messenger RNAs in glucocorticoid-resistant human multiple myeloma cells. Cancer Res, 1993; 53: 3877–9.
Longui, C. A., Vottero, A., Adamson, P. C., et al.Low glucocorticoid receptor alpha/beta ratio in T-cell lymphoblastic leukemia. Horm Metab Res, 2000; 32: 401–6.
Haarman, E. G., Kaspers, G. J. L., Pieters, R., et al.Glucocorticoid receptor alpha, beta and gamma expression versus in vitro glucocorticod resistance in childhood leukemia. Leukemia, 2004; 18: 530–7.
Hillmann, A. G., Ramdas, J., Multanen, K., et al.Glucocorticoid receptor gene mutations in leukemic cells acquired in vitro and in vivo. Cancer Res, 2000; 60: 2056–62.
Kojika, S., Sugita, K., Inukai, T., et al.Mechanisms of glucocorticoid resistance in human leukemic cells: implication of abnormal 90 and 70 kDa heat shock proteins. Leukemia, 1996; 10: 994–9.
Kullmann, M., Schneikert, J., Moll, J., et al.RAP46 is a negative regulator of glucocorticoid receptor action and hormone-induced apoptosis. J Biol Chem, 1998; 273: 14 620–5.
Lauten, M., Beger, C., Gerdes, K., et al.Expression of heat-shock protein 90 in glucocorticoid-sensitive and -resistant childhood acute lymphoblastic leukaemia. Leukemia, 2003; 17: 1551–6.
Gerritsen, M. E., Williams, A. J., Neish, A. S., et al.CREB-binding protein/p300 are transcriptional coactivators of p65. Proc Natl Acad Sci U S A, 1997; 94: 2927–32.
Tissing, W. J., Meijerink, J. P., Boer, M. L., et al.mRNA expression levels of (co)chaperone molecules of the glucocorticoid receptor are not involved in glucocorticoid resistance in pediatric ALL. Leukemia, 2005; 19: 727–33.
Zelcer, N., Reid, G., Wielinga, P., et al.Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem J, 2003; 371: 361–7.
Boer, M. L., Pieters, R., Kazemier, K. M., et al.Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia. Blood, 1998; 91: 2092–8.
Kearns, P. R., Pieters, R., Rottier, M. M., et al.Raised blast glutathione levels are associated with an increased risk of relapse in childhood acute lymphocytic leukemia. Blood, 2001; 97: 393–8.
Boer, M. L., Pieters, R., Kazemier, K. M., et al.Different expression of glutathione S-transferase α, μ and π in childhood acute lymphoblastic and myeloid leukaemia. Br J Haematol, 1999; 104: 321–7.
Reichardt, H. M., Kaestner, K. H., Tuckermann, J., et al.DNA binding of the glucocorticoid receptor is not essential for survival. Cell, 1998; 93: 531–41.
Bailey, S., Hall, A. G., Pearson, A. D., et al.The role of AP-1 in glucocorticoid resistance in leukaemia. Leukemia, 2001; 15: 391–7.
Kordes, U., Krappmann, D., Heissmeyer, V., et al.Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells. Leukemia, 2000; 14: 399–402.
Liptay, S., Seriu, T., Bartram, C. R., et al.Germline configuration of NFkB2, c-REL and BCLl3 in childhood acute lymphoblastic leukemia (ALL). Leukemia, 1997; 11: 1364–6.
Thulasi, R., Harbour, D. V., & Thompson, E. B.Suppression of c-myc is a critical step in glucocorticoid-induced human leukemic cell lysis. J Biol Chem, 1993; 268: 18 306–12.
Conte, D., Liston, P., Wong, J. W., et al.Thymocyte-targeted overexpression of xiap transgene disrupts T lymphoid apoptosis and maturation. Proc Natl Acad Sci U S A, 2001; 98: 5049–54.
Miller, H. K., Salzer, J. S., & Balis, M. E.Amino acid levels following L-asparaginase amidohydrolase (EC.3.5.1.1) therapy. Cancer Res, 1969; 29: 183–7.
Ohnuma, T., Holland, J. F., Freeman, A., et al.Biochemical and pharmacological studies with asparaginase in man. Cancer Res, 1970; 30: 2297–305.
Jousse, C., Bruhat, A., Ferrara, M., et al.Evidence for multiple signaling pathways in the regulation of gene expression by amino acids in human cell lines. J Nutr, 2000; 130: 1555–60.
Aslanian, A. M., Fletcher, B. S., & Kilberg, M. S.Asparagine synthetase expression alone is sufficient to induce l-asparaginase resistance in MOLT-4 human leukaemia cells. Biochem J, 2001; 357: 321–8.
Stams, W. A., Boer, M. L., Holleman, A., et al.Asparagine synthetase expression is linked with L-asparaginase resistance in TEL-AML1-negative but not TEL-AML 1-positive pediatric acute lymphoblastic leukemia. Blood, 2005; 105: 4223–5.
Dubbers, A., Wurthwein, G., Muller, H. J., et al.Asparagine synthetase activity in paediatric acute leukaemias: AML-M5 subtype shows lowest activity. Br J Haematol, 2000; 109: 427–9.
Aslanian, A. M. & Kilberg, M. S.Multiple adaptive mechanisms affect asparagine synthetase substrate availability in asparaginase-resistant MOLT-4 human leukaemia cells. Biochem J, 2001; 358: 59–67.
Iiboshi, Y., Papst, P. J., Hunger, S. P., et al.L-Asparaginase inhibits the rapamycin-targeted signaling pathway. Biochem Biophys Res Commun, 1999; 260: 534–9.
Hu, Z. B., Minden, M. D., & McCulloch, E. A.Regulation of drug sensitivity by ribosomal protein S3a. Blood, 2000; 95: 1047–55.
Holleman, A., Cheok, M. H., Boer, M. L., et al.Gene expression patterns in drug resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med, 2004; 351: 533–42.
Mandelkow, E. & Mandelkow, E. M.Microtubules and microtubule-associated proteins. Curr Opin Cell Biol, 1995; 7: 72–81.
Kavallaris, M., Tait, A. S., Walsh, B. J., et al.Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells. Cancer Res, 2001; 61: 5803–9.
Giannakakou, P., Nakano, M., Nicolaou, K. C., et al.Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics. Proc Natl Acad Sci U S A, 2002; 99: 10855–60.
Boer, M. L., Pieters, R., Kazemier, K. M., et al.Relationship between the intracellular daunorubicin concentration, expression of major vault protein/lung resistance protein and resistance to anthracyclines in childhood acute lymphoblastic leukemia. Leukemia, 1999; 13: 2023–30.
Boer, M. L., Pieters, R., Kazemier, K. M., et al.The modulating effect of PSC 833, cyclosporin A, verapamil and genistein on in vitro cytotoxicity and intracellular content of daunorubicin in childhood acute lymphoblastic leukemia. Leukemia, 1998; 12: 912–20.
Siva, A. C., Raval-Fernandes, S., Stephen, A. G., et al.Up-regulation of vaults may be necessary but not sufficient for multidrug resistance. Int J Cancer, 2001; 92: 195–202.
Legrand, O., Simonin, G., Beauchamp-Nicoud, A., et al.Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia. Blood, 1999; 94: 1046–56.
Goasguen, J. E., Lamy, T., Bergeron, C., et al.Multifactorial drug resistance phenomenon in acute leukemias: impact of P170-MDR1, LRP56 protein, glutathion-transferases and methallothione systems on clinical outcome. Leuk Lymphoma, 1996; 23: 567–76.
Kakihara, T., Tanaka, A., Watanabe, A., et al.Expression of multidrug resistance-related genes does not contribute to risk factors in newly diagnosed childhood acute lymphoblastic leukemia. Pediatr Int, 1999; 41: 641–7.
Borg, A. G., Burgess, R., Green, L. M., et al.P-glycoprotein and multidrug resistance-associated protein, but not lung resistance protein, lower the intracellular daunorubicin accumulation in acute myeloid leukaemic cells. Br J Haematol, 2000; 108: 48–54.
Tsuji, K., Motoji, T., Sugawara, I., et al.Significance of lung resistance-related protein in the clinical outcome of acute leukaemic patients with reference to P-glycoprotein. Br J Haematol, 2000; 110: 370–8.
Leith, C. P., Kopecky, K. J., Chen, I. M., et al.Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1 and LRP in acute myeloid leukemia: a Southwest Oncology Group study. Blood, 1999; 94: 1086–99.
Heuvel-Eibrink, M. M., Sonneveld, P., & Pieters, R.The prognostic significance of membrane transport-associated multidrug-resistance (MDR) proteins in leukemia. Int J Clin Pharmacol Ther, 2000; 38: 94–110.
Bezombes, C., de Thonel, A., Apostolou, A., et al.Overexpression of protein kinase C zeta confers protection against antileukemic drugs by inhibiting the redox-dependent sphingomyelinase activation. Mol Pharmacol, 2002; 62: 1446–55.
Batist, G., Schecter, R., Woo, A., et al.Glutathione depletion in human and in rat multi-drug resistant breast cancer cell lines. Biochem Pharmacol, 1991; 41: 631–5.
Versantvoort, C. H. M., Broxterman, H. J., Bagrij, T., et al.Regulation of glutathione of drug transport in multidrug-resistant human lung tumour cell lines overexpressing multidrug resistance-associated protein. Br J Cancer, 1995; 72: 82–9.
Kaufmann, S. H., Karp, J. E., Jones, R. J., et al.Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia. Blood, 1994; 83: 517–30.
Klumper, E., Giaccone, G., Pieters, R., et al.Topoisomerase IIa gene expression in childhood acute lymphoblastic leukemia. Leukemia, 1995; 9: 1653–60.
Gieseler, F., Glasmacher, A., Kämpfe, D., et al.Topoisomerase II activities in AML blasts and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxins. Leukemia, 1996; 10: 1177–80.
Hellin, A. C., Bentires-Alj, M., Verlaet, M., et al.Roles of nuclear factor-kappaB, p53, and p21/WAF1 in daunomycin-induced cell cycle arrest and apoptosis. J Pharmacol Exp Ther, 2000; 295: 870–8.
Holleman, A., Boer, M. L., Kazemier, K. M., et al.Resistance to different classes of drugs is associated with impaired apoptosis in childhood acute lymphoblastic leukemia. Blood, 2003; 102: 4541–6.
Friesen, C., Herr, I., Krammer, P. H., et al.Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med, 1996; 2: 574–7.
Landowski, T. H., Gleason-Guzman, M. C., & Dalton, W. S.Selection for drug resistance results in resistance to Fas-mediated apoptosis. Blood, 1997; 89: 1854–61.
Labroille, G., Dumain, P., Lacombe, F., et al.Flow cytometric evaluation of Fas expression in relation to response and resistance to anthracyclines in leukemic cells. Cytometry, 2000; 39: 195–202.
Debatin, K. M. & Krammer, P. H.Resistance to APO-1 (CD95) induced apoptosis in T-ALL is determined by a bcl-2 independent anti-apoptotic program. Leukemia, 1995; 9: 815–20.
Karawajew, L., Wuchter, C., Ruppert, V., et al.Differential CD95 expression and function in T and B lineage acute lymphoblastic leukemia cells. Leukemia, 1997; 11: 1245–52.
Wuchter, C., Karawajew, L., Ruppert, V., et al.Constitutive expression levels of CD95 and Bcl-2 as well as CD95 function and spontaneous apoptosis in vitro do not predict the response to induction chemotherapy and relapse rate in childhood acute lymphoblastic leukaemia. Br J Haematol, 2000; 110: 154–60.
Munker, R. & Andreeff, M.Induction of death (CD95/Fas), activation and adhesion (CD54) molecules on blast cells of acute myelogenous leukemias by TNF-α and IFN-gamma. Cytokines Mol Ther, 1996; 2: 147–60.
Iijima, N., Miyamura, K., Itou, T., et al.Functional expression of Fas (CD95) in acute myeloid leukemia cells in the context of CD34 and CD38 expression: possible correlations with sensitivity to chemotherapy. Blood, 1997; 90: 4901–9.
Jaffrezou, J. P., Levade, T., Bettaieb, A., et al.Daunorubicin-induced apoptosis: triggering of ceramide generation through sphingomyelin hydrolysis. EMBO J, 1996; 15: 2417–24.
Itoh, M., Kitano, T., Watanabe, M., et al.Possible role of ceramide as an indicator of chemoresistance: decrease of the ceramide content via activation of glucosylceramide synthase and sphingomyelin synthase in chemoresistant leukemia. Clin Cancer Res, 2003; 9: 415–23.
Chikamori, K., Grabowski, D. R., Kinter, M., et al.Phosphorylation of serine 1106 in the catalytic domain of topoisomerase II alpha regulates enzymatic activity and drug sensitivity. J Biol Chem, 2003; 278: 12 696–702.
Bugg, B. Y., Danks, M. K., Beck, W. T., et al.Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide. Proc Natl Acad Sci U S A, 1991; 88: 7654–8.
Danks, M. K., Warmoth, M. R., Friche, E., et al.Single-strand conformational polymorphism analysis of the M(r) 170,000 isozyme of DNA topoisomerase II in human tumor cells. Cancer Res, 1993; 53: 1373–9.
Rots, M. G., Pieters, R., Kaspers, G. J., et al.Classification of ex vivo methotrexate resistance in acute lymphoblastic and myeloid leukaemia. Br J Haematol, 2000; 110: 791–800.
Gorlick, R., Goker, E., Trippett, T., et al.Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression. Blood, 1997; 89: 1013–18.
Matherly, L. H., Taub, J. W., Wong, S. C., et al.Increased frequency of expression of elevated dihydrofolate reductase in T-cell versus B-precursor acute lymphoblastic leukemia in children. Blood, 1997; 90: 578–89.
Zhang, L., Taub, J. W., Williamson, M., et al.Reduced folate carrier gene expression in childhood acute lymphoblastic leukemia: relationship to immunophenotype and ploidy. Clin Cancer Res, 1998; 4: 2169–77.
Belkov, V. M., Krynetski, E. Y., Schuetz, J. D., et al.Reduced folate carrier expression in acute lymphoblastic leukemia: a mechanism for ploidy but not lineage differences in methotrexate accumulation. Blood, 1999; 93: 1643–50.
Laverdiere, C., Chiasson, S., Costea, I., et al.Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood, 2002; 100: 3832–4.
Whetstine, J. R., Gifford, A. J., Witt, T., et al.Single nucleotide polymorphisms in the human reduced folate carrier: characterization of a high-frequency G/A variant at position 80 and transport properties of the His(27) and Arg(27) carriers. Clin Cancer Res, 2001; 7: 3416–22.
Gifford, A. J., Haber, M., Witt, T. L., et al.Role of the E45K-reduced folate carrier gene mutation in methotrexate resistance in human leukemia cells. Leukemia, 2002; 16: 2379–87.
Mantadakis, E., Smith, A. K., & Kamen, B. A.Ratio of methotrexate to folate uptake by lymphoblasts in children with B-lineage acute lymphoblastic leukemia: a pilot study. J Pediatr Hematol Oncol, 2000; 22: 221–6.
Zeng, H., Chen, Z. S., Belinsky, M. G., et al.Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res, 2001; 61: 7225–32.
Chen, Z. S., Lee, K., Walther, S., et al.Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res, 2002; 62: 3144–50.
Assaraf, Y. G., Rothem, L., Hooijberg, J. H., et al.Loss of multidrug resistance protein 1 expression and folate efflux activity results in a highly concentrative folate transport in human leukemia cells. J Biol Chem, 2003; 278: 6680–6.
Whitehead, V. M., Rosenblatt, D. S., Vuchich, M. J., et al.Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts at diagnosis of childhood acute lymphoblastic leukemia: a pilot prognostic factor analysis. Blood, 1990; 76: 44–9.
Mantadakis, E., Smith, A. K., Hynan, L., et al.Methotrexate polyglutamation may lack prognostic significance in children with B-cell precursor acute lymphoblastic leukemia treated with intensive oral methotrexate. J Pediatr Hematol Oncol, 2002; 24: 636–42.
Galpin, A. J., Schuetz, J. D., Masson, E., et al.Differences in folylpolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts: mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity. Mol Pharmacol, 1997; 52: 155–63.
Barredo, J. C., Synold, T. W., Laver, J., et al.Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia. Blood, 1994; 84: 564–9.
Longo, G. S., Gorlick, R., Tong, W. P., et al.Disparate affinities of antifolates for folylpolyglutamate synthetase from human leukemia cells. Blood, 1997; 90: 1241–5.
Goker, E., Waltham, M., Kheradpour, A., et al.Amplification of the dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphoblastic leukemia and is correlated with p53 gene mutations. Blood, 1995; 86: 677–84.
Spencer, H. T., Sorrentino, B. P., Pui, C. H., et al.Mutations in the gene for human dihydrofolate reductase: an unlikely cause of clinical relapse in pediatric leukemia after therapy with methotrexate. Leukemia, 1996; 10: 439–46.
Krajinovic, M., Costea, I., & Chiasson, S.Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukaemia. Lancet, 2002; 359: 1033–4.
Chiusolo, P., Reddiconto, G., Casorelli, I., et al.Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate. Ann Oncol, 2002; 13: 1915–18.
Taub, J. W., Matherly, L. H., Ravindranath, Y., et al.Polymorphisms in methylenetetrahydrofolate reductase and methotrexate sensitivity in childhood acute lymphoblastic leukemia. Leukemia, 2002; 16: 764–5.
Dervieux, T., Blanco, J. G., Krynetski, E. Y., et al.Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells. Cancer Res, 2001; 61: 5810–6.
Coulthard, S. A., Hogarth, L. A., Little, M., et al.The effect of thiopurine methyltransferase expression on sensitivity to thiopurine drugs. Mol Pharmacol, 2002; 62: 102–9.
Davidson, J. D.Studies on the mechanism of action of 6-mercaptopurine in sensitive and resistant L1210 leukemia in vitro. Cancer Res, 1960; 20: 225.
Brockman, R. W.A mechanism of resistance to 6-mercaptopurine: metabolism of hypoxanthine and 6-mercaptopurine by sensitive and resistant neoplasms. Cancer Res, 1960; 20: 643.
Ellis, D. B. & LePage, G. A.Biochemical studies of resistance to 6-thioguanine. Cancer Res, 1963; 23: 436.
Zimm, S., Johnson, G. E., Chabner, B. A., et al.Cellular pharmacokinetics of mercaptopurine in human neoplastic cells and cell lines. Cancer Res, 1985; 45: 4156–61.
Brockman, R. W.Resistance to purine antagonists in experimental leukemia systems. Cancer Res, 1965; 25: 1596–605.
Curt, G. A., Clendeninn, N. J., & Chabner, B. A.Drug resistance in cancer. Cancer Treat Rep, 1984; 68: 87–99.
Pieters, R., Huismans, D. R., Loonen, A. H., et al.Hypoxanthine-guanine phosphoribosyltransferase in childhood leukemia: relation with immunophenotype, differentiation stage, in vitro drug resistance and clinical prognosis. Int J Cancer, 1992; 51: 213–17.
Pieters, R., Huismans, D. R., Loonen, A. H., et al.Adenosine deaminase and purine nucleoside phosphorylase in childhood leukemia; relation with differentiation stage, clinical prognosis and in vitro drug resistance. Leukemia, 1992; 6: 375–80.
Veerman, A. J. P., Hogeman, P. H. G., Zantwijk, C. H. Van., et al.Prognostic value of 5′ nucleotidase in acute lymphoblastic leukemia with the common-ALL phenotype. Leuk Res, 1985; 9: 1227–9.
Pieters, R., Huismans, D. R., & Veerman, A. J.Are children with lymphoblastic leukaemia resistant to 6-mercaptopurine because of 5′-nucleotidase ?Lancet, 1987; 2: 1471.
Pieters, R., Thompson, L. F., Broekema, G. J., et al.Expression of 5′-nucleotidase (CD73) related to other differentiation antigens in leukemias of B-cell lineage. Blood, 1991; 78: 488–92.
Pieters, R., Huismans, D. R., Loonen, A. H., et al.Relation of 5′-nucleotidase and phosphatase activities with immunophenotype, drug resistance and clinical prognosis in childhood leukemia. Leuk Res, 1992; 16: 873–80.
Rosman, M., Lee, M. H., Creasey, W. A., et al.Mechanisms of resistance to 6-thiopurines in human leukemia. Cancer Res, 1974; 34: 1952–6.
Lennard, L. & Lilleyman, J. S.Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol, 1989; 7: 1816–23.
Lilleyman, J. S. & Lennard, L.Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia. Lancet, 1994; 343: 1188–90.
McLeod, H. L., Relling, M. V., Liu, Q., et al.Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood, 1995; 85: 1897–902.
Lennard, L., Welch, J. C., & Lilleyman, J. S.Thiopurine drugs in the treatment of childhood leukaemia: the influence of inherited thiopurine methyltransferase activity on drug metabolism and cytotoxicity. Br J Clin Pharmacol, 1997; 44: 455–61.
Krynetski, E. Y., Tai, H. L., Yates, C. R., et al.Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics, 1996; 6: 279–90.
Coulthard, S. A., Howell, C., Robson, J., et al.The relationship between thiopurine methyltransferase activity and genotype in blasts from patients with acute leukemia. Blood, 1998; 92: 2856–62.
McLeod, H. L., Krynetski, E. Y., Relling, M. V., et al.Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia, 2000; 14: 567–72.
Relling, M. V., Hancock, M. L., Boyett, J. M., et al.Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood, 1999; 93: 2817–23.
Owens, J. K., Shewach, D. S., Ullman, B., et al.Resistance to 1-beta-D-arabinofuranosylcytosine in human T-lymphoblasts mediated by mutations within the deoxycytidine kinase gene. Cancer Res, 1992; 52: 2389–93.
Flasshove, M., Strumberg, D., Ayscue, L., et al.Structural analysis of the deoxycytidine kinase gene in patients with acute myeloid leukemia and resistance to cytosine arabinoside. Leukemia, 1994; 8: 780–5.
Heuvel-Eibrink, M. M., Wiemer, E. A., Kuijpers, M., et al.Absence of mutations in the deoxycytidine kinase (dCK) gene in patients with relapsed and/or refractory acute myeloid leukemia (AML). Leukemia, 2001; 15: 855–6.
Taub, J. W., Huang, X., Matherly, L. H., et al.Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin. Blood, 1999; 94: 1393–400.
Veuger, M. J., Honders, M. W., Landegent, J. E., et al.High incidence of alternatively spliced forms of deoxycytidine kinase in patients with resistant acute myeloid leukemia. Blood, 2000; 96: 1517–24.
Veuger, M. J., Heemskerk, M. H., Honders, M. W., et al.Functional role of alternatively spliced deoxycytidine kinase in sensitivity to cytarabine of acute myeloid leukemic cells. Blood, 2002; 99: 1373–80.
Boos, J., Hohenlochter, B., Schulze-Westhoff, P., et al.Intracellular retention of cytosine arabinoside triphosphate in blast cells from children with acute myelogenous and lymphoblastic leukemia. Med Pediatr Oncol, 1996; 26: 397–404.
Braess, J., Wegendt, C., Feuring-Buske, M., et al.Leukaemic blasts differ from normal bone marrow mononuclear cells and CD34+ haemopoietic stem cells in their metabolism of cytosine arabinoside. Br J Haematol, 1999; 105: 388–93.
Galmarini, C. M., Thomas, X., Calvo, F., et al.In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia. Br J Haematol, 2002; 117: 860–8.
Verschuur, A. C., Gennip, A. H.Leen, R., et al.In vitro inhibition of cytidine triphosphate synthetase activity by cyclopentenyl cytosine in paediatric acute lymphocytic leukaemia. Br J Haematol, 2000; 110: 161–9.
Steinbach, D., Wittig, S., Cario, G., et al.The multidrug resistance-associated protein 3 (MRP3) is associated with a poor outcome in childhood ALL and may account for the worse prognosis in male patients and T-cell immunophenotype. Blood, 2003; 102: 4493–8.
Steinbach, D., Lengemann, J., Voigt, A., et al.Response to chemotherapy and expression of the genes encoding the multidrug resistance-associated proteins MRP2, MRP3, MRP4, MRP5, and SMRP in childhood acute myeloid leukemia. Clin Cancer Res, 2003; 9: 1083–6.
Kolk, D. M., De Vries, E. G., Noordhoek, L., et al.Activity and expression of the multidrug resistance proteins P-glycoprotein, MRP1, MRP2, MRP3 and MRP5 in de novo and relapsed acute myeloid leukemia. Leukemia, 2001; 15: 1544–53.
Heuvel-Eibrink, M. M., Wiemer, E. A., & Prins, A., et al.Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML). Leukemia, 2002; 16: 833–9.
Steinbach, D., Sell, W., Voigt, A., et al.BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia. Leukemia, 2002; 16: 1443–7.
Sargent, J. M., Williamson, C. J., Maliepaard, M., et al.Breast cancer resistance protein expression and resistance to daunorubicin in blasts from patients with acute myeloid leukemia. Br J Haematol, 2001; 115: 257–62.
Stam, R. W., Heuvel-Eibrink, M. M., Boer, M. L., et al.Multidrug resistance genes in infant acute lymphoblastic leukemia; Ara-C is not a substrate for the breast cancer resistance protein (BCRP). Leukemia, 2004; 18: 78–83.
Sauerbrey, A., Sell, W., Steinbach, D., et al.Expression of the BCRP gene (ABCG2/MXR/ABCP) in childhood acute lymphoblastic leukaemia. Br J Haematol, 2002; 118: 147–50.
Kumagai, M., Manabe, A., Pui, C. H., et al.Stroma-supported culture in childhood B-lineage acute lymphoblastic leukemia cells predicts treatment outcome. J Clin Invest, 1996; 97: 755–60.
Schimmer, A. D., Pedersen, I. M., Kitada, S., et al.Functional blocks in caspase activation pathways are common in leukemia and predict patient response to induction chemotherapy. Cancer Res, 2003; 63: 1242–8.
Salomons, G. S., Smets, L. A., Verwijs-Janssen, M, et al.Bcl-2 family members in childhood acute lymphoblastic leukemia: relationships with features at presentation, in vitro and in vivo drug response and long-term clinical outcome. Leukemia, 1999; 13: 1574–80.
Coustan-Smith, E., Kitanaka, A., Pui, C. H., et al.Clinical relevance of bcl-2 overexpression in childhood acute lymphoblastic leukemia. Blood, 1996; 87: 1140–6.
Wuchter, C., Ruppert, V., Schrappe, M., et al.In vitro susceptibility to dexamethasone- and doxorubicin-induced apoptotic cell death in context of maturation stage, responsiveness to interleukin 7, and early cytoreduction in vivo in childhood T-cell acute lymphoblastic leukemia. Blood, 2002; 99: 4109–15.
Prokop, A., Wieder, T., Sturm, I., et al.Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax/Bcl-2 ratio and loss of spontaneous caspase-3 processing in vivo. Leukemia, 2000; 14: 1606–13.
Cheok, M. H., & Boer, M. L.. Identification of genes associated crossresistance and treatment response in childhood acute leukemia. Cancer Cell, 2005; 7: 375–86.
Cheok, M. H., Yang, W., Pui, C. H., et al.Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells. Nat Genet, 2003; 34: 85–90.
Yeoh, E. J., Ross, M. E., Shurtleff, S. A., et al.Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell, 2002; 1: 133–43.
Armstrong, S. A., Staunton, J. E., Silverman, L. B., et al.MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet, 2002; 30: 41–7.
Ross, M. E., Zhou, X., Song, G., et al.Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood, 2003; 102: 2951–9.
Yagi, T., Morimoto, A., Eguchi, M., et al.Identification of a gene expression signature associated with pediatric AML prognosis. Blood, 2003; 102: 1849–56.
Armstrong, S. A., Kung, A. L., Mabon, M. E., et al.Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell, 2003; 3: 173–83.
Cancel
Confirm
×